头颈癌患者术前药物预防是否安全用于静脉血栓栓塞预防?
该回顾性队列研究纳入539例Caprini风险评分≥5且接受≥3小时住院手术的头颈癌患者,其中427例接受术前药物预防。术前药物预防与出血风险升高相关(比值比8.74,95%CI 1.15-66.5),且未降低静脉血栓栓塞发生率。
要点
- 术前药物预防组大出血发生率高于对照组(427例中34例 vs 112例中36例,P=0.03)。
- 多因素分析仅术前药物预防与出血相关(比值比8.74,95%CI 1.15-66.5)。
- 静脉血栓栓塞发生率为1.3%,两组间无显著差异。
核心结论
- 术前药物预防与头颈癌患者出血增加相关,且未降低静脉血栓栓塞发生率。
- 本研究强调需确定该患者队列中药物预防的最佳方案。
研究设计与样本
- 回顾性队列研究,纳入2015年至2020年间Caprini风险评分≥5且接受≥3小时住院手术的头颈癌患者539例。
- 患者分为术前药物预防组(427例)和对照组(112例),依据是否在术前接受单剂低分子肝素或普通肝素。
主要发现
- 大出血发生率为6.7%。
- 术前药物预防组较对照组更常同时使用阿司匹林或酮咯酸(427例中225例 vs 112例中36例;P=0.0002)。
- 术前药物预防组药物预防持续时间更长(7.8天 vs 5.0天;P<0.0001),Caprini风险评分更高(7.2 vs 6.6;P<0.0001),手术时间更长(596分钟 vs 512分钟;P<0.0001),失血量更多(265 ml vs 214 ml;P=0.02),出血率更高(427例中34例;P=0.03)。
- 多因素分析中,仅术前药物预防与出血相关(比值比8.74;95%CI 1.15-66.5)。
- 静脉血栓栓塞发生率为1.3%,两组间无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the safety of preoperative chemoprophylaxis (PEC) in head and neck cancer (HNC) patients undergoing oncologic procedures. STUDY DESIGN: Retrospective cohort study. SETTING: Tertiary academic center. METHODS: HNC patients with Caprini risk score (CRS) ≥5 who underwent inpatient surgery ≥3 hours between 2015 and 2020 were included. Patients were divided into 2 cohorts, PEC and control, based on whether or not they received a single dose of low molecular weight heparin or unfractionated heparin prior to surgery. The primary endpoint was the 30-day rate of major bleeding events. RESULTS: A total of 539 patients were included; 427 patients received PEC prior to surgery. The rate of major bleeding was 6.7%. The PEC cohort was more likely to have received concurrent aspirin or ketorolac (225 of 427 patients vs 36 of 112 patients; P = .0002), greater duration of chemoprophylaxis (7.8 vs 5.0 days; P < .0001), have higher CRS (7.2 vs 6.6; P < .0001), longer operative times (596 vs 512 minutes; P < .0001), higher blood loss (265 vs 214 ml; P = .02), and higher bleeding rates when compared to the control (34 of 427 patients; P = .03). On multivariate analysis, only PEC was associated with bleeding (odds ratio, 8.74; 95% confidence interval, 1.15-66.5). The rate of VTE was 1.3% and was not significantly different between cohorts. CONCLUSION: PEC was associated with an increase in bleeding and did not result in lower rates of VTE in patients with HNC. This study highlights the need to determine the optimal regimen of chemoprophylaxis in this patient cohort.
引用
- Isaac H, Arnold MA, Pagedar NA, et al. Is Preoperative Chemoprophylaxis Safe for Venous Thromboembolism Prevention in Patients With Head and Neck Cancer? Otolaryngol Head Neck Surg. 2024. PMID: 38943444. doi:10.1002/ohn.875
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。